Pharsight

Drugs that contain Halobetasol Propionate; Tazarotene

1. Duobrii patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6517847 BAUSCH Topical gel delivery system
Aug, 2020

(3 years ago)

US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US11839656 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(7 years from now)

US11679115 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US10426787 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US10251895 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

US11648256 BAUSCH Topical compositions and methods for treating psoriasis
Jun, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2022

Market Authorisation Date: 25 April, 2019

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of DUOBRII before it's drug patent expiration?
More Information on Dosage

DUOBRII family patents

Family Patents